Paul Trippier, PhD

Associate Professor and Director, Pharmaceutical Sciences Graduate Program

Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
986125 Nebraska Medical Center
Omaha, NE 68198-6125
402-559-9763 (Office)
402-559-5673 (Fax)


Teaching Activities:

Dr. Trippier lectures in Medicinal Chemistry and Drug Discovery

Research Activities/Interests:

Dr. Trippier’s research is focused on small molecule drug discovery for cancer and neurodegenerative diseases. His lab employs synthetic medicinal chemistry, chemical biology and molecular pharmacology techniques to design, optimize and employ biologically active compounds as chemical probes to interrogate novel pathways relevant to human disease and as lead compounds for novel drug discovery.

Discoveries in the Trippier lab have led to the identification of the most potent and selective Aldo-keto reductase 1C3 (AKR1C3) inhibitor which shows significant effect to counter drug resistance in prostate cancer and leukemia; the most potent synthetic succinate dehydrogenase inhibitor yet described with significant anticancer activity; novel multi-targeted agents for neurodegenerative disease therapy; and potent activators of neurolysin for stroke therapy development. This research has been and is currently funded by the NCI, NINDS, various private foundations and the pharmaceutical industry.

 Recent Publications:

  1. Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier; Potent and highly selective aldo-keto reductase 1C3 (AKR1C3) inhibitors act as chemotherapeutic potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. J. Med. Chem. 2019, 62, 3590-3616.
  2. Ahmed Morsy andPaul C. Trippier; Amyloid-Binding Alcohol Dehydrogenase (ABAD) inhibitors for the treatment of Alzheimer’s disease. J. Med. Chem. 2019, 62, 4252-4264.
  3. Joelle Makoukji, Fadi Saadeh, Karl Albert Mansour, Sally El Sitt, Jamal Al Ali, Nihar Kinarivala, Paul C. Trippier and Rose-Mary Boustany; Flupirtine derivatives as potential treatment for the Neuronal Ceroid Lipofuscinoses. Ann. Clin. Transl. Neurol. 2018, 5, 1089-1103.
  4. Kshitij Verma, Nehal Gupta, Tianzhu Zang, Beau Wangtrakluldee, Sanjay K. Srivastava, Trevor M. Penning, and Paul C. Trippier; AKR1C3 inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells. Mol. Cancer Ther. 2018, 17,1833-1845.
  5. Thomas J. Abbruscato and Paul C. Trippier; DARK Classics in Chemical Neuroscience:Methamphetamine. ACS Chem. Neurosci. 2018, 9, 2373-2378.
  6. Nihar Kinarivala, Ronak Patel, Rose-Mary Boustany, Abraham J. Al-Ahmed, and Paul C. Trippier; Discovery of aromatic carbamates that confer neuroprotective activity by enhancing autophagy and inducing the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2). J. Med. Chem. 2017, 60, 9739-9756.
  7. Hezhen Wang, Bader Huwaimel, Kshitij Verma, James Miller, Todd M. Germain, Nihar Kinarivala, Dimitri Pappas, Paul S. Brookes and Paul C. Trippier; Synthesis and antineoplastic evaluation of mitochondrial complex II (succinate dehydrogenase) inhibitors derived from Atpenin A5. ChemMedChem, 2017, 12, 1033-1044.
  8. Nihar Kinarivala, Kaushik Shah, Thomas J. Abbruscato and Paul C. Trippier; Passage variation in PC12 cells results in inconsistent susceptibility to externally induced apoptosis. ACS Chem. Neurosci. 2017, 8, 82-88.
  9. Kshitij Verma, Tianzhu Zang, Nehal Gupta, Trevor M. Penning, and Paul C. Trippier; Selective AKR1C3 inhibitors potentiate chemotherapeutic activity in multiple acute myeloid leukemia (AML) cell lines. ACS Med. Chem. Lett. 2016, 7, 774-779.
  10. Paul C. Trippier; Selecting good ‘drug-like’ properties to optimize small molecule blood-brain barrier penetration. Curr. Med. Chem. 2016, 23, 1392-1407.